The study identified fast-tracked drugs in Europe and the U.S., and tracked their therapeutic value ratings to judge effectiveness at treating clinical conditions.
The study determined that 39 percent of the medications granted accelerated approval had therapeutic effectiveness, and 38 percent that were granted conditional market authorization had effectiveness.
Out of 146 medications, 122 were for cancer treatment.
In 2020, 53 percent of cancer-related drugs were fast tracked by the FDA.
In 1992, the FDA created an accelerated drug pathway for medications that could end serious diseases.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
